Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2012 |
| gptkbp:ATCCode |
L01XE21
|
| gptkbp:brand |
gptkb:cabozantinib
|
| gptkbp:chemicalFormula |
gptkb:cabozantinib_citrate
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
gptkb:Exelixis
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cometriq
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hypertension weight loss |
| gptkbp:target |
gptkb:VEGFR
gptkb:RET gptkb:MET |
| gptkbp:usedFor |
medullary thyroid cancer
|
| gptkbp:bfsParent |
gptkb:Exelixis
gptkb:cabozantinib |
| gptkbp:bfsLayer |
6
|